Elicio Therapeutics (NASDAQ:ELTX) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

Posted by on Jun 18th, 2026

Equities research analysts at LADENBURG THALM/SH SH assumed coverage on shares of Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) in a research note issued on Thursday. The firm set a “buy” rating and a $12.00 price target on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 206.44% from the company’s previous close.

Several other equities research analysts have also issued reports on ELTX. HC Wainwright raised their price target on shares of Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. JonesTrading downgraded Elicio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Wall Street Zen lowered Elicio Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, B. Riley Financial initiated coverage on Elicio Therapeutics in a research report on Wednesday, June 10th. They set a “buy” rating and a $27.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Read Our Latest Research Report on ELTX

Elicio Therapeutics Stock Performance

ELTX traded down $0.79 during trading on Thursday, hitting $3.92. 1,923,678 shares of the company traded hands, compared to its average volume of 693,735. The firm has a market cap of $74.74 million, a P/E ratio of -1.63 and a beta of 1.13. The stock’s fifty day moving average is $10.96 and its 200 day moving average is $9.85. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 5.75. Elicio Therapeutics has a one year low of $2.66 and a one year high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.16). As a group, equities analysts predict that Elicio Therapeutics will post -2.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ELTX. Bank of America Corp DE grew its stake in Elicio Therapeutics by 186.8% in the 3rd quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after buying an additional 2,335 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Elicio Therapeutics during the second quarter worth $46,000. Summit Financial LLC purchased a new stake in shares of Elicio Therapeutics during the fourth quarter worth $80,000. HighTower Advisors LLC bought a new position in shares of Elicio Therapeutics in the fourth quarter worth $89,000. Finally, Jane Street Group LLC purchased a new position in shares of Elicio Therapeutics in the first quarter valued at $92,000. 35.03% of the stock is owned by institutional investors.

Elicio Therapeutics Company Profile

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Featured Articles

Analyst Recommendations for Elicio Therapeutics (NASDAQ:ELTX)

Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.